SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Tiwari RC, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2004; 54: 829.
  • 2
    Diamandidis D, Huber M, Pisters K. Non-small cell lung cancer. In: Medical oncology: a comprehensive review. Available from URL: http://cancernetwork.com/textbook/morev12.htm (accessed November 2, 2004).
  • 3
    Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States. Cancer. 1999; 86: 18671876.
  • 4
    Shepherd FA. Current paradigms in first-line treatment of non-small-cell lung cancer. Oncology. 2004; 18(Suppl): 1320.
  • 5
    Hino M, Kobayashi K, Hayashihara K, et al. In vitro combination effect of docetaxel (RP56976) with vinca alkaloids on cancer cell line [abstract 1780]. Proc Am Assoc Cancer Res. 1995; 36: 299.
  • 6
    Aoe K, Ueoka H, Kiura K, et al. Synergistic effect of docetaxel (DCT) and vinorelbine (VNB) against in vitro growth of a human small-cell lung cancer line [abstract 2560]. Proc Am Assoc Cancer Res. 1996; 37: 375.
  • 7
    Aoe K, Kiura K, Ueoka H, et al. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res. 1999; 19: 291300.
  • 8
    Bennouna J, Monnier A, Riviere A, et al. A Phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer. Eur J Cancer. 2000; 36: 11071112.
  • 9
    Kourousis C, Androulakis N, Kakolyris S, et al. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine. Cancer. 1998; 83: 20832090.
  • 10
    Sanchez JM, Balana C, Font A, et al. Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Lung Cancer. 2002; 38: 309315.
  • 11
    Miller VA. Docetaxl (taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a Phase I/II trial. Semin Oncol. 1997; 24(Suppl 14): S14S17.
  • 12
    Miller VA, Krug LM, Ng KK, et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000; 18: 13461350.
  • 13
    Cesano A, Lane SR, Ross GA, Fields SZ. Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non-small cell lung cancer patients. Int J Oncol. 2000; 17: 587590.
  • 14
    Monnerat C, Chevalier TL, Kelly K, et al. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res. 2004; 10: 54395446.
  • 15
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 9298.
  • 16
    Bunn PA. Advances in lung cancer therapy. Toxicol Pathol. 2003; 31: 147148.
  • 17
    Waters JS, O'Brien MER. The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). Br J Cancer. 2002; 87: 481490.
  • 18
    Citron ML, Berry DA, Cirrinicione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003; 21: 14311439.
  • 19
    Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004; 104: 626633.
  • 20
    Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004; 104: 634641.
  • 21
    Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ, for the Medical Research Council Lung Cancer Working Party. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. J Clin Oncol. 2000; 18: 395404.